LifeSci Capital Maintains Crinetics(CRNX.US) With Buy Rating, Maintains Target Price $82

Moomoo NewsNov 22 15:31 ET · Ratings

Promising Outlook for Crinetics Pharmaceuticals' Paltusotine in Phase 3 Trial Drives Buy Rating

TipRanksNov 22 14:35 ET · Ratings

Crinetics Pharmaceuticals to Participate in Three Upcoming December Investor Conferences

GlobeNewswireNov 15 09:00 ET

Crinetics Pharmaceuticals Third Quarter 2024 Earnings: US$0.96 Loss per Share (Vs US$1.01 Loss in 3Q 2023)

Yahoo FinanceNov 14 07:38 ET

Citi Maintains Crinetics(CRNX.US) With Buy Rating, Raises Target Price to $74

Moomoo NewsNov 14 07:31 ET · Ratings

Crinetics Pharmaceuticals: Promising Future With Innovative Drug Developments and Strong Financial Position

TipRanksNov 14 02:38 ET